Baksh: Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial

Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial

Baksh et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad023, CSSC-004, NCT04373460 (history)

Baksh et al., Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a.., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad023, CSSC-004, NCT04373460

Jan 2023 Source PDF

Twitter
Facebook

All Studies Meta

RCT 1,070 outpatients in the USA, showing no significant difference in recovery with convalescent plasma treatment.

Important missing comments or errors? Let us know.

risk of no recovery, 1.0% higher, RR 1.01, p = 0.62, treatment 381 of 538 (70.8%), control 381 of 532 (71.6%), NNT 125, inverted to make RR<1 favor treatment, day 14.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Baksh et al., 31 Jan 2023, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 26 authors, study period 3 June, 2020 - 1 October, 2021, average treatment delay 6.0 days, trial NCT04373460 (history) (CSSC-004).

All Studies All Outcomes Submit Updates or Corrections

This Paper Conv. Plasma All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit